{"prompt": "['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 22 of 122', 'Eligible subjects will be randomly assigned 2:1 to AR101 treatment or standard of care', 'alone. Randomization will be stratified by age group (4-12 years and 13-17 years). Subjects', 'in both treatment groups and their parents/caregivers will have disease-specific and', 'nondisease-specific HRQOL assessments at screening and periodically thereafter.', 'Subjects receiving AR101 treatment will have 3 consecutive AR101 dosing periods before', 'exiting (completing) the study: initial dose escalation, up-dosing, and maintenance. Subjects', 'receiving standard of care alone will have approximately 18 months of observation before', 'exiting (completing) the study. Subjects in both treatment groups will have a graded OLFC', 'up to a maximum single highest dose of 1000 mg of peanut protein (2043 mg cumulative),', 'approximately 12 months after randomization.', 'AR101 Treatment Group', 'Initial dose escalation: Subjects randomly assigned to AR101 treatment will begin with a', 'stepwise dose escalation of AR101 (up to 5 single doses of 0.5, 1, 1.5, 3, and 6 mg)', 'administered at 20- to 30-minute intervals as tolerated at the study site.', 'Subjects who tolerate at least 3 mg of AR101 on day 1 will return to the study site on', 'day 2 to receive a single confirmatory 3 mg dose under direct observation. Subjects', 'who tolerate the 3 mg confirmatory dose with no or mild symptoms that are not', 'dose-limiting will begin the up-dosing period.', 'Subjects who do not tolerate at least 3 mg of AR101 on day 1 or day 2 will stop', 'AR101 treatment and discontinue early from the study.', 'Up-dosing: The up-dosing period will be approximately 6 months (22-40 weeks). Dose', 'escalation will occur approximately every 2 weeks. Daily AR101 doses during up-dosing', 'will be 3, 6, 12, 20, 40, 80, 120, 160, 200, 240, and 300 mg/day. The first dose of AR101 at', 'each new dose level will be administered under direct observation at the study site; the', 'remaining doses at each dose level will be administered daily at home as tolerated. Subjects', 'able to tolerate 300 mg for 2 weeks will begin the maintenance period. Subjects unable to', 'tolerate 300 mg/day for 2 weeks within 40 weeks of up-dosing will stop AR101 treatment', 'and discontinue early from the study.', 'Maintenance: Subjects will continue AR101 daily dosing at 300 mg/day for an additional', '12 months (52 weeks) with study site visits every 4 weeks. After at least 6 months (up to', '7 months) of maintenance treatment (approximately 12 months after randomization/first dose', 'of AR101), subjects will have a graded OLFC up to a maximum single highest dose of', '1000 mg of peanut protein (3, 10, 30, 100, 300, 600, 1000 mg [2043 mg cumulative]).', 'Subjects who tolerate 1000 mg of peanut protein (2043 mg cumulative) at the OLFC', 'will continue AR101 daily at 300 mg/day and will have the option to consent for', 'a real-world peanut challenge (RWPC) within 4 weeks (preferably within 1 week)', 'after the OLFC. During the RWPC, subjects will eat a food containing 500 to 600 mg', 'of peanut protein under direct observation at the study site. Subjects who complete']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 23 of 122', 'the RWPC (regardless of the outcome) will continue daily maintenance treatment', 'with AR101 at 300 mg/day for a total of 52 weeks of maintenance until study exit.', 'Subjects who tolerate at least 300 mg but < 1000 mg of peanut protein (2043 mg', 'cumulative) at the OLFC or tolerate 1000 mg of peanut protein (2043 mg cumulative)', 'but do not consent to the optional RWPC will continue daily maintenance treatment', 'with AR101 at 300 mg/day for a total of 52 weeks of maintenance until study exit.', 'Subjects who do not tolerate at least 300 mg of peanut protein at the OLFC will stop', 'AR101 treatment and discontinue early from the study.', 'Standard of Care Treatment Group', 'Subjects receiving standard of care alone will have approximately 18 months of observation', 'before study exit, with an OLFC approximately 12 months after randomization. Subjects', 'receiving standard of care alone who complete the OLFC will not have an RWPC.', 'Both Treatment Groups', 'Early discontinuation: Subjects with unresolved adverse events at early discontinuation or', 'who had GI adverse events of interest will have safety follow-up (Section 5.5).', 'Subjects who discontinue AR101 treatment early before completing 9 months of', 'maintenance, and their parents/caregivers, will complete relevant follow-up HRQOL', 'questionnaires (Section 5.3.1).', 'Study exit: Subjects with unresolved adverse events at study exit or who had GI adverse', 'events of interest will have safety follow-up (Section 5.5). AR101-treated subjects who', 'complete approximately 12 months of maintenance treatment at 300 mg/day will have the', 'option to enroll in an open-label follow-on study to continue AR10 treatment until it', 'becomes commercially available or its development is terminated. Subjects who receive', 'standard of care alone and complete approximately 18 months of observation will also have', 'the option to receive AR101 treatment in a follow-on study. Subjects may continue to', 'receive AR101 maintenance treatment or standard of care alone in ARC009 if the open-label', 'follow-on study is not activated at their study site when subjects complete their course of', 'treatment/observation.', '3.2', 'Study Schematic', 'The study schematic is provided in Figure 1.']\n\n###\n\n", "completion": "END"}